key: cord-0882700-0prx2rfp
authors: Chakhalian, Daniel; Shultz, Robert B.; Miles, Catherine E.; Kohn, Joachim
title: Opportunities for biomaterials to address the challenges of COVID‐19
date: 2020-08-04
journal: J Biomed Mater Res A
DOI: 10.1002/jbm.a.37059
sha: 5965ed6295564eebf5fa65b113db59bf7dfeab22
doc_id: 882700
cord_uid: 0prx2rfp

The coronavirus disease 2019 (COVID‐19) pandemic has revealed major shortcomings in our ability to mitigate transmission of infectious viral disease and provide treatment to patients, resulting in a public health crisis. Within months of the first reported case in China, the virus has spread worldwide at an unprecedented rate. COVID‐19 illustrates that the biomaterials community was engaged in significant research efforts against bacteria and fungi with relatively little effort devoted to viruses. Accordingly, biomaterials scientists and engineers will have to participate in multidisciplinary antiviral research over the coming years. Although tissue engineering and regenerative medicine have historically dominated the field of biomaterials, current research holds promise for providing transformative solutions to viral outbreaks. To facilitate collaboration, it is imperative to establish a mutual language and adequate understanding between clinicians, industry partners, and research scientists. In this article, clinical perspectives are shared to clearly define emerging healthcare needs that can be met by biomaterials solutions. Strategies and opportunities for novel biomaterials intervention spanning diagnostics, treatment strategies, vaccines, and virus‐deactivating surface coatings are discussed. Ultimately this review serves as a call for the biomaterials community to become a leading contributor to the prevention and management of the current and future viral outbreaks.

COVID-19 illustrates that the biomaterials community was engaged in significant research efforts against bacteria and fungi with relatively little effort devoted to viruses. Accordingly, biomaterials scientists and engineers will have to participate in multidisciplinary antiviral research over the coming years. Although tissue engineering and regenerative medicine have historically dominated the field of biomaterials, current research holds promise for providing transformative solutions to viral outbreaks. To facilitate collaboration, it is imperative to establish a mutual language and adequate understanding between clinicians, industry partners, and research scientists. In this article, clinical perspectives are shared to clearly define emerging healthcare needs that can be met by biomaterials solutions. Strategies and opportunities for novel biomaterials intervention spanning diagnostics, treatment strategies, vaccines, and virus-deactivating surface coatings are discussed.

Ultimately this review serves as a call for the biomaterials community to become a leading contributor to the prevention and management of the current and future viral outbreaks. 19 . Regardless of this growing trend, much of the biomaterial community has focused their research on antibacterial work; a cursory search on Pubmed, as of May 2020, shows 90 articles including the keywords "biomaterial and antiviral" in the last 5 years, but over 3,500 results for the same search with "biomaterial and antibacterial."

To facilitate rapid problem solving and scientific advancement during this viral pandemic, it is our goal to review the current clinical practices against COVID-19 and how current and future biomaterials work can contribute.

The SARS-CoV-2 virus was first identified in December 2019 in Wuhan Province, China as a cluster of pneumonias. 2 Since then, the virus has spread globally at an astonishing rate and is expected to SARS cases and 774 deaths (9.2% mortality) were reported in total across 29 countries. The majority of these cases were people in close contact with animals and healthcare workers who were associated with aerosol generating procedures while the overall human-tohuman transmission was limited. 4 The MERS outbreak began in September 2012 in Saudi Arabia and by June 2019, 2,500 cases and 845 deaths (34.5% mortality) were reported in total across 27 countries. A similar transmission pattern to SARS is documented, with overall limited human-to-human transmission. 5 Although all three are zoonotically transmitted novel coronaviruses, COVID-19 differentiates itself significantly in how widely and quickly it has spread, and how low the mortality rate is compared to the other two viruses. 4, 5 To illustrate this point, consider that SARS and MERS were found to have a basic reproduction number (R 0 ), a measure of how contagious an infectious disease is, between 2.5 and 3.5, whereas the most recent estimates for COVID-19 are around 4-9 making it at least twice as contagious. 6 Not only is this number important to project rate of spread, but R 0 is directly related to the concept of herd immunitythat in a given population, a threshold of immunized individuals confers protection from pathogen transmission to the unimmunized individuals. The basic relationship between R 0 and herd immunity is the "herd immunity threshold" and is calculated as 1-1/R 0 . 7 Given this equation, diseases with an R 0 of 3 would require 67% of the population be immunized to achieve the herd immunity threshold, whereas an R 0 of 5.5, such as COVID-19, would require 82% to be immunized. 8 Taxonomically, SARS-CoV-2 is an enveloped positive sense RNA virus and part of the beta-coronavirus family ( Figure 1 ). The viral genome is around 30 kb and is divided into several open reading frames which encode both structural and nonstructural proteins. 9 Following successful entry into cells, viral RNA is released into the cell cytoplasm, where positive-sense RNA is translated by host cells into proteins. The structural proteins include spike (S) glycoprotein, envelope (E) glycoprotein, membrane (M) glycoprotein, and nucleocapsid (N) protein. 10 Briefly, the S protein interfaces with angiotensin-converting enzyme 2 (ACE2) to fuse with host cells and is of great interest for ongoing research. The E protein assists with assembly and budding of new virions in the endoplasmic reticulum. The M protein is the main structural protein. The N protein binds to viral RNA and is involved in processing and stabilizing the RNA. 10, 11 Nonstructural proteins (NSPs) include enzymes that assemble to form replication-transcription complexes involved in viral replication. 12, 13 Replication is believed to take place within a network of modified endoplasmic reticulum membranes. Following assembly, virions are released via exocytosis into the surrounding extracellular space, where they go on to infect other host cells or are expelled or excreted from the body.

While originally a zoonotic virus, the primary method of transmission has transitioned to human-to-human via close contact, fomites, and droplet. 14 Of great concern is the "asymptomatic carrier"a patient who sheds the virus for days to weeks before symptoms occur, if at all. 15 Additionally, there is growing evidence that SARS-CoV-2 is highly contagious partly due to its ability to travel in aerosols, which are widely defined as small respirable droplets <5 to 10 μm in diameter. Unlike large (>20 μm) droplets, these small aerosols do not immediately settle due to gravity but are instead capable of long-range airborne transport. 16, 17 Once the particles are inhaled, pathogenesis begins in the lungs due to direct invasion of host epithelial cells. This creates a localized inflammatory response driven by several cytokinemediated pathways. It has been shown that S protein interaction with ACE2 activates a signaling pathway which significantly upregulates chemokine (C-C motif) ligand 2 production (CCL2), a cytokine which attracts T cells, monocytes and basophils. 18 Another important pathway involves intracellular antigenic peptide presentation via major histocompatibility complex (MHC) to cytotoxic T lymphocytes. These immune triggers are also responsible for a systemic inflammatory F I G U R E 1 Structure of SARS-CoV-2 virus particle. Nucleocapsid (N), envelope (E), and spike (S) proteins along with matrix form a shell surrounding single-stranded (ss) RNA. Reproduced with permission from Astuti et al. 10 response which can range from a normal immune response to a cytokine storm-an uncontrolled production and circulation of pro-inflammatory cytokines which can damage other organ systems and lead to superinfection, acute respiratory disease syndrome (ARDS), cardiac injury, stroke, and multi-organ dysfunction. [18] [19] [20] The largest clinical report on COVID-19 (72,314 cases) was published by the Chinese Center for Disease Control (CDC) and was summarized in the Journal of the American Medical Association in February 2020. It categorized patients by clinical manifestation into mild (81%), severe (14%), and critical infection (5%) groups. 21 Symptoms ranged from headache, gastroenteritis, and cough for mild infection, to ventilator-dependent respiratory failure, sepsis and multi-organ dysfunction (MOD) for those critically infected. 2, 19 No fatalities were reported for mild and severe cases, but in critical infections the case fatality rate approached 50%. These numbers are similar to smaller studies in the United States. 22, 23 Treatment of these patients revolves largely around supportive respiratory care and targeted intervention of secondary injuries. Successively more severe stages of acute respiratory failure require successively more invasive treatments. In practice respiratory status is monitored by using a pulse oximeter to assess blood oxygen saturation (SpO 2 ), a measure of the percentage of hemoglobin which is oxygenated, with a target saturation of >90%. The most basic oxygen treatment includes the use of low flow nasal cannula. The next step up includes high flow nasal oxygen (HFNO) and noninvasive ventilation (NIV) treatments. These are newer therapies that show promise in decreasing intubation rates and intensive care unit (ICU) mortality and length of stay. HFNO utilizes a specialized nasal cannula to deliver high volumes of oxygen and due to such high flow also improves the physiology of breathing. NIV uses an oro-nasal mask to deliver mechanical ventilation and oxygenation without the need for intubation. 24, 25 However, if a patient continues to be hypoxic on these therapies then intubation with invasive mechanical ventilation becomes necessary. The details of ventilator management is outside the scope of this paper, but if a patient continues to be hypoxic despite maximum ventilatory support, then extracorporeal membrane blood oxygenation (ECMO) is a final rescue therapy. Such critically ill patients almost uniformly suffer from ARDS which severely inhibits oxygen diffusion across their lung alveolar membranes. ECMO bypasses the lungs and affords the patient time to recover by using a device to drain, perform gas exchange on, and then recirculate oxygenated blood back to the patient. 26 Despite their necessity, all these oxygen treatments carry risk to healthcare workers with viral particle aerosolization from the intubation procedure carrying the highest risk.

Following the outbreak of the COVID-19 pandemic, SARS-CoV-2 rapidly became one of the most important subjects in biomedical research.

In the following sections, we outline a series of focus areas for biomaterials researchers by first providing a brief description of current clinical standards and then opportunities for biomaterials intervention. In many cases, multidisciplinary approaches involving biomaterials are expected to play a major role in disease detection and management. 

Current SARS-CoV-2 RT-PCR testing has several limitations at sample collection and processing stages, introducing bottlenecks in testing workflows and severely limited access to testing in regions that lack PCR instrumentation infrastructure. Given these limitations, point-ofcare (POC) strategies are an attractive alternative and accordingly are a subject of current research. As the name implies, POC tests can rapidly provide diagnoses without requiring off-site laboratory processing of samples. Ideally, POC solutions eliminate the need for specialized equipment, allowing tests to be conducted in the field or even selfadministered at home. This dramatically reduces the risk of disease spread during centralized testing and processing, increases testing throughput and capacity, and expands testing access for less developed or lower income areas. Biomaterials research can provide key solutions to the challenges and limitations faced by current diagnostic approaches. At the most rudimentary level, biomaterials laboratories can help manufacture key disposables, including test swabs used to collect specimens. For example, the company Formlabs has developed and validated 3D printed nasal swabs for collection of respiratory samples. 28 Beyond offsetting disposables shortages, biomaterials can also play a supporting role in the development of POC tests. Emerging POC nucleic acid tests combine state-of-the-art molecular and synthetic biology discoveries with biomaterials advances to facilitate low technology disease detection. 27 To bypass instrumentation needs, multidisciplinary research is now underway to develop novel methods of purifying genetic material from complex biological samples, amplifying genetic material of interest, detecting target sequences, and conveying those results in simple and intuitive ways. [29] [30] [31] [32] Isothermal RT-PCR tests

In conjunction with emerging biology-based advances, biomaterials scientists can contribute important technologies to facilitate nextgeneration diagnostic test development. To aid in nucleic acid purification for example, Ali et al. developed a magnetic nanoparticlebased scheme that allowed for rapid isolation of RNA and DNA from biological samples via application of a magnetic field. 33 In the same study, the authors also developed a magnetic nanoparticle-based chemiluminescent reporter system that allowed for detection of target sequences with relatively simple instrumentation. Biomaterials also form the basis of colorimetric readout options that allow for interpretation of assay results without the use of any specialized optics, making them ideal tests for POC detection. Biomaterialsbased surface plasmon resonance biosensors such as gold nanoparticles or quantum dots have been demonstrated to change color according to size, shape, surface chemistry, and aggregation state thus making them excellent optical probes. 34, 35 This can be exploited to produce simple colorimetric readouts from complex molecular reactions. 10 An alternative colorimetric method involves the use of RNA toehold switches coupled with paper-based, cell-free protein expression platforms. Although traditionally RNA has not been considered a biomaterial, a recent definition expands the field to include any material "designed to take a form that can direct, through interaction with biological systems, the course of any therapeutic or diagnostic procedure." 37 This includes materials built from biomolecules, such as RNA, using synthetic biology principles, as reflected by the increasing number of synthetic biology-focused sessions that are now held at major biomaterials conferences. RNA toehold switches are rationally designed, synthetic RNA molecules comprised of toehold and coding regions separated by a hairpin structure that blocks translation by sequestering the ribosome-binding site and start codon. Upon exposure to a specific trigger RNA, the target sequence binds to the toehold region to induce a conformational shift, unfolding the hairpin and allowing for ribosome binding and subsequent gene expression (Figure 2b ). Pardee et al. designed toehold switches that, in combination with ribosomes, generated LacZ enzyme upon exposure to Zikaderived trigger RNA. 38 When substrate was added to the mix, colored product was generated by the enzyme, resulting in easy detection by the naked eye. To improve detection limits, an isothermal amplification step was added, allowing viral RNA to be converted into cDNA, amplified, and then converted back into RNA to trigger toehold Most importantly, all test reagents (including buffers, enzymes, ribosomes, and substrates) could be lyophilized onto a single paper disk, allowing for one-step testing of clinical samples. In addition to requiring minimal instrumentation this platform was shown to be highly economical, expanding access to testing. Work is currently underway to extend this technology to develop tests for COVID-19. 39 Both the CRISPR and RNA-toehold based detection strategies make use of enzymatic reporter systems that not only transduce but also amplify signal. Conventional nucleic acid probes allow for signal growth in direct proportion to target sequence accumulation, but enzymatic reporters allow for exponential relationships between target sequence concentration and signal intensity. When combined with excellent specificity, this can theoretically allow for detection of much lower concentrations of target nucleic acids. From a COVID-19 perspective, lower detection limits could allow for detection of exceptionally low viral loads associated with asymptomatic but infectious patients.

Emerging biosensors with ultra-low limits of detection may one day allow for complete elimination of reverse transcription and/or cDNA amplification steps, providing faster and simpler one-step detection. 43 In the presence of copolymer, nanomolar concentrations of MNAzymes could detect picomolar amounts of target sequence at physiological temperature.

Protein tests are employed to detect viral antigens or antibodies raised against them. While the presence of viral antigens indicates active infection, antibodies can take several days to appear in the blood. 2, 44 Thus, antibody tests are more routinely used to demonstrate evidence of previous infection. Although it is currently unclear if blood antibodies raised against SARS-CoV-2 confer immunity, antibody tests are still expected to prove useful for disease tracking and surveillance as well as for monitoring vaccine efficacy. In addition, as the relationship between antibodies and immunity is further revealed, individuals testing positive for antibodies may be able to resume normal daily activities on a shorter timeline or even donate plasma to aid in the treatment of sick patients. To date, enzyme-linked immunosorbent assays (ELISAs) and other immunoassays have been used to screen for the presence of antibodies raised against SARS-CoV-2N or S protein antigens. Significantly more FDA EUAs have been granted to immunoglobulin (Ig) G tests over IgM, most likely because IgM responses generally precede IgG responses and fade quickly, while serum levels of IgG antibodies are sustained and believed to be more closely related to conferred immunity. 45 Lateral flow immunoassays and ELISA Biomaterials make the basis for emerging immunoassays for antibody detection. In many cases, colloidal gold-antigen conjugates can be used as optical probes. 46 For example, Cellex™ offers a gold nanoparticle-based lateral flow assay for detection of IgG and IgM antibodies.

When sample is added to the test strip, antibodies in the sample bind to antigen immobilized onto the particle surface. In the event of a positive test, two strips of anti-human IgG or IgM secondary antibody located further along the strip capture gold complexes, resulting in the development of a dark red line. Magnetic nanoparticles have also found use in antibody detection applications-the biotechnology company Abbott has been granted an EUA for an IgG test that utilizes viral antigen-coated magnetic nanoparticles. Nanoparticles can be immobilized after capturing antibodies, washed extensively, and tagged with anti-human IgG conjugates capable of producing chemiluminescent signals.

In the US, several ELISA-based tests have also been granted EUA status. ELISAs typically exhibit lower limits of detection than colloidal gold lateral flow assays because they include a signal amplification step-when antibodies of interest are present, captured enzymes generate detectable product. In addition, ELISAs typically use 96-well plate formats or similar, allowing many samples to be tested at once.

Despite these advantages, processing of samples can be labor-intensive and involves many wash steps that can introduce error. In addition, samples must be processed at centralized facilities, resulting in increased turnaround times. Microfluidics allow for the design of POC ELISA tests that require very little user input. [47] [48] [49] Microfluidic lab-ona-chip devices consist of micron-scale channels and chambers and allow multi-step diagnostic assays to be conducted rapidly and efficiently. 50 For broad surveillance of population antibody titers, these microfluidic ELISA tests are appealing-they can be conducted in the field, reduce user error, dramatically reduce required sample volume, can also probe for other viral antigens, but disruption of viral particle structure is required. For example, Quidel® received EUA for a fluorescent immunoassay-based antigen test that detects viral N proteins.

The approach requires virus to first be denatured and uses a cassettebased lateral flow sandwich immunoassay that generates fluorescent outputs that must be read with an instrument also sold by the firm.

In addition to diagnostics development, biomaterials technologies can be employed to develop novel treatment strategies for effective management of COVID-19 infection. In the following section, opportunities for biomaterials-based strategies are discussed.

Traditional antiviral therapies can be classified into non-specific antiviral agents (e.g., ribavirin, remdesivir, chloroquine) and targeted inhibitors of a specific viral element (e.g., HIV protease inhibitors, RNAi). [58] [59] [60] [61] In addition, immunomodulatory agents (e.g., interferons and corticosteroids) have been used to decrease the inflammatory state associated with viral infection. These therapies are compelling but also have major shortcomings. Nonspecific antivirals are generally more prophylactic, not effective against all viruses, and can have significant side effect profiles. 59, 61, 62 At the same time, targeted inhibitors are definitionally limited by their specificity to one target and offer no guarantee of efficacy in future viral outbreaks. Finally, immunomodulation to control cytokine storm carries risk of suppressing beneficial parts of the immune response to the point of harm. In the case of SARS-CoV-2, it is fortunate that there is a large degree of similarity to previous viral outbreaks, otherwise a considerable amount of time would be required to find new targets and develop therapies against them. Instead, the acute and pressing need for treatment options has resulted in attempts to repurpose existing drugs. 63, 64 Several drugs have come to the forefront of the medical and research community, including hydroxychloroquine, remdesivir, and dexamethasone. Hydroxychloroquine is a drug with multiple mechanisms of action, illustrated by its use as an antimalarial and anti-inflammatory in several rheumatological diseases. Three main proposed mechanisms in COVID-19 include blocking viral entry into host cells, decreased viral replication, and anti-inflammatory properties. 65 Despite initial promise, hydroxychloroquine serves as a reminder to the medical community that even during a pandemic robust clinical data are required to make informed recommendations for treatments with known, severe side effects. Another consideration is the sudden shortage of hydroxychloroquine and the effect it has had on rheumatological patients who rely on it for chronic treatment. 66, 67 Remdesivir is a broad spectrum antiviral prodrug which is converted to a nucleoside analog in cells and has been shown to be effective against Ebola, SARS-CoV and MERS in vitro. 68 It is currently being studied in randomized studies with preliminary data supporting use in hospitalized COVID-19 patients requiring oxygen therapy, though once again further data are pending. 69 Dexamethasone is a strong synthetic corticosteroid with anti-inflammatory and immunosuppressive mechanisms of action. 70 Based on the current data from the RECOVERY trial, dexamethasone is the most promising repurposed drug with significant data showing decreased mortality in patients requiring either invasive or noninvasive oxygen therapy. 71 Despite these heroic efforts, relatively little progress has been made toward the development of COVID-19 therapeutics that directly target SARS-CoV-2. Instead, hospitalized patients are provided with symptomatic relief, repurposed compassionate-use drugs and life-supporting interventions while they fight off the viral infection, as previously described. Biomaterials offers several opportunities to address the limitations of existing therapeutic strategies (Figure 3) .

Drug candidates may directly inhibit viral processes including infection or replication, modulate pro-inflammatory cytokine signaling, or stimulate regenerative healing processes. Unfortunately, many of these drug candidates are not ideally suited for systemic administration using standard oral or intravenous routes. Antibodies, anti-inflammatory cytokines, and other protein-based drugs often exhibit short halflives, while sufficiently hydrophobic drugs suffer from low accumulation in target tissue. In addition, many existing antiviral medications demonstrate significant off-target effects that hinder clinical use. 72 For example, some drug candidates that were found to robustly inhibit SARS-CoV-2 infection and replication in vitro did not yield clinical success in vivo due to adverse off-target effects. 63,73-75 When therapeutic concentrations of a potential drug cannot be safely achieved in target tissue, use becomes infeasible, as lower doses confer no therapeutic benefit while higher doses cause safety concerns.

Drug delivery systems can be designed to administer less drug overall while selectively targeting affected tissue, dramatically reducing systemic exposure and expanding the candidate pool of potential drugs. In addition, delivery of drugs with poor stability or low bioavailability to targets of interest can be more readily achieved. In our lab, this concept has already been applied to challenging hydrophobic cancer therapeutics by using novel self-assembling tyrosine-derived polymeric nanospheres (Tyrospheres) to minimize toxic side effects and maintain bioactivity. [76] [77] [78] [79] Tyrospheres and other polymeric particle systems built from commonly used polyesters have been shown to locally deliver immunosuppressants and antibacterial therapeutics. [80] [81] [82] Other methods of creating polymeric drug delivery devices include electrospun fibermats and drug eluting stents. [83] [84] [85] These techniques can be used to overcome the challenges of implementing current therapeutics for COVID-19 that have failed due to unacceptably severe side effects. Because SARS-CoV-2 has been shown to target the lung epithelial tissue, formulation of drug delivery systems such as polymeric particles as inhalants may hold promise and have previously been demonstrated for treatment of other diseases like lung cancers. 86, 87 Concerns have been raised regarding the potential for exhaled particles to aerosolize viruses and facilitate disease spread, but careful design of particle size may be able to ameliorate this risk. 88 Notably, inhalants could be administered at home, or even as a prophylactic measure. For intubated patients, drug-eluting coatings of endotracheal tubes placed into the airway could similarly target affected tissue while sparing the rest of the body; such coatings have been previously reported. 89 

In an alternate nanomaterials-centered strategy, nanostructures can be designed to mimic living cells. These particles, called nanodecoys, 

Another therapeutic strategy involves the use of extracorporeal blood treatments to mitigate the most damaging aspects of COVID-19.

ECMO devices are used clinically for the most critically ill patients, but these machines are typically in even shorter supply than ventilators, are costly to operate, and are typically only found at specialized centers. 92, 93 Alternatively, emerging nanoparticle and microparticle oxygen carriers could lead to the development of more accessible extracorporeal blood oxygenation strategies. 94 For severely ill patients however, oxygenation alone may not be sufficient to reduce mortality rates. A recent retrospective analysis of Chinese patient data revealed that almost half of the COVID-19 patients treated with ECMO still died from septic shock or multi-organ failure. 63 With that in mind, the ideal vaccine elicits a robust immune response characterized by sustained antibody production and conferred immunity across a large and diverse patient population. Biomaterials strategies to augment conventional vaccine design and development have been extensively reviewed. 47, 106 The key advantage to biomaterials-based approaches is enhanced control over the vaccination process. Conventional vaccine strategies are essentially comprised of one to several bolus injections of antigenic material, while engineered systems allow for fine manipulation of antigen delivery rate and presentation as well as host immune cell response. As our understanding of acquired immunity continues to evolve, biomaterials can provide the tools for precise immune modulation.

Multiple biomaterials-based solutions such as nanoparticles, liposomes, scaffolds, and microneedles have been proposed. Nanoscale structures can be designed to protect antigen cargo, present antigens in biomimetic formats, and allow for specific immune cell targeting. 47 This can be achieved by leveraging modifications in nanoparticle size, shape, surface chemistry (particle charge, hydrophobicity), and material composition. 107 Microneedles are applied topically and slowly dissolve allowing for pain-free sustained antigen delivery into the skin, a highly immune-reactive organ. 108 antigen-specific antibody responses in mice. 113 Ongoing efforts to develop the MERS vaccine were then applied to rapidly design and produce a similar microneedle vaccine based on SARS-CoV-2 S protein subunit trimers that similarly showed promise in mice. Plans are underway to coordinate a first-in-man Phase I clinical trial. 45 In some cases, polymeric materials may also act as adjuvants. Adjuvants are broadly defined as a substance that enhances the antigenicity of an antigen. Babensee et al. have shown that certain biomaterials have the ability to selectively upregulate the differentiation and maturation of dendritic cells, which play an important role in antigen presentation, and therefore act as adjuvants. 114 Another example of this is when mice mounted robust antibody responses to bovine serum albumin when antigen was delivered from subcutaneously implanted biodegradable tyrosine-derived polymer devices. 115 This was due to adjuvant activity of one of the polymer degradation byproducts. In addition, anti-bovine serum albumin (BSA) antibody titers were significantly higher when BSA was delivered from tyrosine-derived polymer devices as compared to poly(bisphenol A-iminocarbonate) controls.

As previously discussed, the main method of virus spread is through aerosolized particles. Large droplets (>20 μm) land on surfaces close to the point of emission while small droplets (<5-10 μm) begin to evaporate and become small enough to be transported by air several meters from the point of emission. 116 A major problem with viruses is their ability to remain active on surfaces. In this way, contaminated surfaces such as doorknobs, toilet handles, tables, and utensils used in restaurants, and touch screens can facilitate viral transfer from sick to healthy individuals. While surfaces can be sanitized with a variety of household cleaners, sterilizing after each individual use is difficult to maintain. This is especially problematic for areas with a high concentration of infected patients or a particularly susceptible population such as hospitals or senior living facilities. Surface stability varies by virus, but according to a recent study, SARS-CoV-2 can remain active on plastic, stainless steel, and cardboard for 3.8, 5.8, and 6.5 hr, respectively at a temperature of 21-23 C with 40% humidity. 117 Strategies aimed at mitigating viral spread generally look to deactivate viruses upon landing on surfaces. 118, 119 Existing antiviral surfaces see limited use in clinical practice even though ongoing research supporting different biomaterials coatings has been around for decades. 120, 121 Biomaterials have been used for virus inactivation and have great potential to help combat the spread of SARS-CoV-2 and future viral outbreaks. [122] [123] [124] Indeed, reformulating antiviral materials as virucidal surface coatings can attenuate contamination of surfaces and minimize disease propagation. 125, 126 In addition, antiviral biomaterials coatings can be applied to conventional personal protective equipment (PPE) to allow for multiple uses. 127

Biomaterials coatings with known antiviral properties can be made from metals, surfactants, and natural products. Metals, especially silver, gold, and copper have been used for decades as antiviral agents. [128] [129] [130] It is important to acknowledge the NIH and FDA's guidance on silver particles and that colloidal silver can cause serious side effects and are not meant for internal ingestion. 131, 132 Silver nanoparticles have shown to inactivate HIV-1, herpes simplex virus type 1, and influenza among other viruses. [133] [134] [135] [136] The nanoparticle size plays a key role in HIV-1 deactivation, where only particles within the range of 1-10 nm are able to bind to the sulfur-bearing residues on the viral envelope. It is proposed that silver's antiviral activity is attributed to the silver nanoparticles physically inhibiting the binding between the virus and the host cell. 137, 138 Gold nanoparticles behave in a similar manner by binding to virus particles thereby blocking the cell receptor and preventing the virus from starting the viral cycle.

These nanoparticles suppress viral infection by selectively cleaving disulfide bonds, which blocks virus membrane fusion to the cell and prevents viral entry into the host cell (Figure 4a ). 139 Gold nanoparticles have also shown to inhibit measles and have low cytotoxicity at viral inhibitory concentrations and may prove useful for viral inactivation for other enveloped viruses. 140 Copper oxide nanoparticles are used to inactivate both enveloped and nonenveloped RNA and DNA viruses. 141 Compared to silver nanoparticles which act as a physical barrier, copper oxide nanoparticles actively damage virus complexes. Copper oxide nanoparticles easily convert between Cu(I) and Cu(II) in vivo, and Cu(II) ions oxidatively damage biomolecules, including viruses. 141 Metal nanoparticles are toxic in vivo causing severe side effects, however by altering the concentration, particle size, or metal coating composition toxicity can be significantly reduced. 142 Mohammadyari, et al. reported that in doses <400 ppm, copper oxide nanoparticles 50 nm in size had no adverse side effects on rat kidney or liver; however, above 400 ppm the particles were toxic. 143 Silver and copper nanoparticles have been incorporated into clothing, wound dressings, and implant coatings due to their antiviral activity. 134 Although incorporation of metal nanoparticles into textiles has been extensively studied, their side effects and toxicity have been less intensively investigated. Due to their small size, nanoparticles can enter the human body through various routes and cause harmful side effects. 144 160 vivo applications, which can be especially useful for incorporation into PPE. Copper's antiviral abilities have shown to be effective for the deactivation of influenza A virus through an increase in copper ion diffusion through the virus' lipid membrane. 145 Incorporation of Cu(II) held in place by zeolites into cotton textiles significantly increased inactivation of avian influenza H5 subtype virus. 146 Binding cationic copper ions into textiles, latex, and other polymer products during manufacture demonstrated virus inactivation properties for HIV-1. 129 In addition to metals, treating textiles with a boron-triclosan mixture showed efficacy at significantly reducing viral activity of human adenovirus and poliovirus type 1 strains. 147 Virus inactivating gloves are of particular interest in today's pandemic which can serve as a way to increase the safety of hospital workers. Incorporation of an anti-infective agent, chlorhexidine, into the interior of examination gloves to deliver the anti-viral agent within 10 minutes of exposure to a liquid has been patented in the 1990s. 148 However, a large amount of antiinfective agent is required which does not provide a cost-effective material.

Surfactants are chemical species that create self-assembled micelles in solution and contain both a hydrophilic and a hydrophobic group. 149 They are often the common active ingredient in household disinfecting agents and have shown high antiviral activity. 150 The use of surfactants as sanitizing agents for virus inactivation has been recently reviewed by Lin et al. 151 Surfactants can be broken down into cationic-often found in fabric softeners, hair conditioners, antiseptic hand wash, and mouthwash; anionic-often found in detergent and personal-care products; nonionic-often found in foaming and emulsifying agents; and zwitterionic species-often found in laundry and cosmetic products. All are capable of inactivating viruses by solvating and disrupting the lipidbased envelope of the virus or by targeting the capsid proteins. [152] [153] [154] [155] [156] [157] [158] [159] Although beneficial as sanitizing agents, surfactants are less commonly used to prepare virus deactivating surfaces. A significant research advancement lies in utilizing these antiviral agents in biomaterials applications. This approach has the potential to minimize the lifespan of viral particles on surfaces thereby minimizing transmission. One method uses surfactants as polymer paints, which can be applied to surfaces to halt the spread of viral infection. Cationic surfactant N,N-dodecyl methylpolyethylenimine (DM-PEI), a quaternary ammonium compound, has shown to be an antibacterial and enveloped antiviral polymer due to its ability to rupture the cell membranes by interaction with the polycationic chains. 160 The DM-PEI coating acts as an adhesive for the virus particle, which immobilizes the virus, and causes damage from the hydrophobic polycation in DM-PEI (Figure 4b) . The virus' genetic material is released leaving residual inactivated virus particle adhered to the substrate surface. Biosurfactants are amphiphilic compounds, mostly produced at the microbial cell surface and are able to accumulate between fluid phases. 161 Similar to chemical surfactants, biosurfactants are used in industrial, agricultural, cosmetic, and pharmaceutical applications. 162 However, biosurfactants can be easily degradable, have a low toxicity, have high availability from raw materials, and often are not affected by environmental factors (pH, temperature, ionic strength). 163 Although mostly used for antimicrobial applications, biosurfactants have been used to inactivate retrovirus, herpes virus, and HIV, among others. 164 Biosurfactants are more commonly used against enveloped viruses due the physicochemical interactions between the virus lipid membrane and the membrane-active surfactant causing viral disintegration. 165 Often biosurfactants are used in preventing biofilm formation and as anti-adhesives in order to prevent bacterial and viral growth. 166 While underdeveloped, the use of surfactants as coatings to achieve antiviral activity has great potential to improve the safety of individuals in high trafficked areas such as airports or in places of high transmission rates such as hospitals.

Many naturally derived products have been used to prevent virus transmission; cellulose has been used in meat products and as the wax coating on fruits and vegetables. 167 Antiviral coatings have been approved for use on food items and packaging to prevent the spread of human noroviruses and hepatitis A virus, among others. 168 These coatings are often made from polysaccharides, cellulose, starch, pectin, alginate, lipids, or other natural polymers and are generally termed safe for ingestion. 169 Active compounds derived or extracted from grape seed, green tea, Aloe vera, Eriobotryae folium, and cinnamaldehyde are a few naturally derived compounds used in active packaging against marine norovirus. [170] [171] [172] Catechins present in green tea extract contain antioxidant, anticarcinogenic, anti-inflammatory and antimicrobial properties and have recently been shown to exhibit antiviral activity against the food-borne pathogens hepatitis A and murine norovirus. 173, 174 Cyclodextrins are another group of naturally occurring macrocyclic molecules that have been used for their virucidal activity. 175 These naturally occurring products are most commonly used in food packaging applications and have not been translated to applications outside of the food industry.

To prevent the spread of human-to-human transmission, face masks have become mandated in many countries when traveling, shopping, or when simply leaving the house. Face masks have received significant review since the beginning of the pandemic; which fabrics are the best for particle filtration, can masks be reused, what are their utility lifespans, and what happens with the extra waste produced when they are discarded. One commonality most often agreed upon is that they are necessary to help filter aerosolized droplets from the air to minimize viral transmission. Existing filtration strategies see more regular clinical use, especially in the context of negative pressure isolation rooms and face masks. Currently they strive to capture viral particles from the air, but do not deactivate the particles. As a result, air filtration devices such as respirators and masks must be changed frequently when exposure to virus is suspected, a practice that contributes to ongoing PPE shortages and contributes to the generation of nondegradable waste. Biomaterials strategies can be employed to develop novel filtration devices capable of capturing and deactivating SARS-CoV-2 and other viruses.

The most commonly used viral filtration devices are face masks.

Masks are a necessary component for the health and safety of individuals who are exposed to aerosolized virus particles; however, not all masks are designed for virus filtration. 176 The most common masks used are (a) surgical masks which are capable of filtering 98% of 3 μm particles making them effective in blocking large-particle droplets, but not able to filter aerosolized particles transmitted by coughs or sneezes; and (b) performance level face masks such as N95 masks which are capable of filtering 95% of 0.1-0.3 μm particles. [177] [178] [179] To reduce the spread and transmission of viruses, it is important to design masks that have a minimum porosity threshold of an individual virus particle-20-300 nm. 180, 181 There is an abundance of current research focusing on chemically modifying masks to provide viral deactivation properties, which would allow for multiple uses, reducing PPE shortages, and nondegradable waste generation. Most masks are made from non-biodegradable, non-renewable petroleum-based polymers that are already contributing to environmental pollution worldwide. 182, 183 To reduce this and future pandemics' environmental impact, it is important to design masks that are made from biodegradable materials or can be multi-use. Ideally, these masks would also have antiviral activity and be more effective at filtering virus particles.

One example of a virus-functionalized mask is by Tiliket et al. who chemically modified the mask layers by incorporating DM-PEI functionalized Kimwipes® Lite (non-woven cellulosic fiber filter) layers into a low-cost commercial medical mask which improved the affinity for trapping airborne influenza virus A (H5N2). 180 Other approaches to modify masks for viral filtration efficacy include the incorporation of natural extracts from green tea (QR-435, catechin, theaflavin) into the masks layers, which successfully block the passage of virus or inactivate viruses by inhibiting viral replication; impregnating copper oxide into N95 respiratory masks to mitigate viral titer recovery of influenza virus; and incorporating sialic acid, which mimics human cell receptor sites, to create an affordable, easy-to-produce filter capable of removing viruses such as influenza. [184] [185] [186] [187] [188] Due to more strict requirements to wear a face covering, Konda et al. studied the efficacy of different commonly available fabrics for preventing the inhalation of aerosol particles. 189 They found that tighter weaves with low porosity (i.e., high thread count cotton sheets) are ideal for mechanical filtration whereas natural silk, chiffon, and flannel provide high electrostatic filtering capabilities. A hybrid mask incorporating both cotton with silk or chiffon had increased filtration efficiency.

Designing and implementing a mask that is able to filter or deactivate virus particles, is cost effective, is environmentally degradable, and has the potential to change the rate of virus spread worldwide.

A similar avenue of research is based on the use of ventilators which typically are fitted with an inhalant and an expiratory filter. However, the chemical make-up of these filters is of extreme importance.

When placed on mechanical ventilation, infected patients can contribute to the spread of the virus through the expiratory valve aerosolizing droplets into ambient air. Several filters, PALL Ultipor® 25, Ultipor® 100, and BB50T among others, are available for use on the expiratory limb of ventilators that have shown to filter >99.999% of H1N1 virus. 190, 191 Most filters fitted on respirators are high efficiency particulate air (HEPA) filters which are adequate for bacterial, dust, pollen, mold filtration, and other particles larger than 0.2 μm in size; however they are not sufficient for virus particle filtration. 32, 191 It is important to design a filtration device that can be attached to ventilators to mitigate the spread of aerosolized virus particles.

Simultaneously, it is important to filter building air, especially in a hospital setting where aerosolized virus particles can be at a high concentration. Buildings are often fitted with HVAC systems that have a filter for airborne pathogens. 192 Robust filters also exist for virus filtration that involve carbon-fiber ionizers designed to generate air ions and charge aerosolized virus particles which allows for the filter to capture the virus particles. 193 Home filter devices have been designed to inactivate common airborne viruses through the use of palladium-titanium dioxide catalysts with vacuum ultraviolet irradiation. 194 It is important to implement these virus filtration systems in high traffic areas or areas with a high virus concentration to create a constant airflow and deactivate virus particles. It has been shown that when virus particles become electrostatically charged, they are attracted to an oppositely charged surface. 195, 196 Hagbom et al.

developed a small-scale device using charged surface technology to both inactivate and filter Influenza A and H1N1 virus particles by placing the device between an infected and healthy individual. 197 It was proposed that reduced virus infectivity is caused by damaging the viral lipid envelope through peroxidation reactions between the reactive oxygen species and the lipid and protein. When the ionizing device was placed between two guinea pig cages, one infected with Influenza A and one healthy, none of the exposed guinea pigs tested positive for influenza-specific immune response serum compared to 75% in exposed guinea pigs where an inactive ionizing device was present. Such a device, if scaled up appropriately, has the potential to be either used in hospital settings where hospital personnel are closely interacting with infected patients or to create a highly sensitive device to capture virus particles to help in the detection and identification of novel viruses. Similar virus filtration and inactivation systems (filtration, microfiltration, hydrophobic or ionic surface modifications) have been studied for their ability to trap viruses during water filtration. 198 Of particular interest is the use of previously mentioned DM-PEI as a polyelectrolyte coating on commercially available microfiltration membranes which not only remove but also inactivate hepatitis E surrogates. 199

Much of our current knowledge stems from the previous viral outbreaks, SARS and MERS, but COVID-19 has transcended those in overall mortality, prevalence, and social and economic impact. This review has described several specific opportunities for the biomaterials community to contribute significantly in the fight against the COVID-19 pandemic. Importantly, this is not an exhaustive list but serves to illustrate a variety of recent advances and future directions for biomaterial research. Given how universal this outbreak has been, global readiness and scientific collaboration are imperative.

Imaging and Bioengineering of the National Institutes of Health under Award Number T32EB005583.

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

And others. Clinical features of patients infected with 2019 novel coronavirus in Wuhan

An interactive web-based dashboard to track COVID-19 in real time

Consensus document on the epidemiology of severe acute respiratory syndrome (SARS): World Health Organization

World Health Organization

High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis

Herd immunity": a rough guide

Understanding herd immunity

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes Metab Syndr

Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein

Coronaviruses -drug discovery and therapeutic options

SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum

And others. COVID-19: a call for physical scientists and engineers

Asymptomatic transmission during the COVID-19 pandemic and implications for public health strategies

Consideration of the aerosol transmission for COVID-19 and public health

Recognition of aerosol transmission of infectious agents: a commentary

Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment

novel coronavirus (2019-nCoV) outbreak: a new challenge

COVID-19 and stroke-a global world stroke organization perspective

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention

Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States

Evans L and others. Covid-19 in critically ill patients in the Seattle region -case series

Respiratory management in severe acute respiratory syndrome coronavirus 2 infection

Non-invasive ventilation or high-flow oxygen therapy: when to choose one over the other?

Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases

Quantum dot-mediated biosensing assays for specific nucleic acid detection

20203D printed test swabs for COVID-19 testing

Field-deployable viral diagnostics using CRISPR-Cas13

Nucleic acid isothermal amplification technologies: a review

Isothermal amplification of nucleic acids

Indoor air quality (IAQ)

Immunization with inactivated middle east respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother

Nanobiosensors based on localized surface plasmon resonance for biomarker detection

Quantum dots for robust and simple assays using single particles in nanodevices

SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat Protoc

Definitions of Biomaterials for the Twenty-First Century

Fan M and others. Rapid, low-cost detection of zika virus using programmable biomolecular components

U of T researcher's 'lab-in-a-box' promises to boost COVID-19 testing capacity

Programmable CRISPRresponsive smart materials

Nanosensors for the detection of viruses

Dualfunctional plasmonic photothermal biosensors for highly accurate severe acute respiratory syndrome coronavirus 2 detection

MNAzyme-catalyzed nucleic acid detection enhanced by a cationic copolymer

Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland

Emergency use authorization (EUA) information, and list of all current EUAs. Emergency Use Authorization

Evaluation of enzyme-linked immunoassay and colloidal gold-Immunochromatographic assay kit for detection of novel coronavirus (SARS-Cov-2) causing an outbreak of pneumonia (COVID-19)

Improving vaccine and immunotherapy design using biomaterials

Microfluidic ELISA employing an enzyme substrate and product species with similar detection properties

Implementation of microfluidic sandwich ELISA for superior detection of plant pathogens

Chapter 15 -microfluidic devices for viral detection

Massively multiplexed nucleic acid detection using Cas13

An alternative medical diagnosis method: biosensors for virus detection

Trends and innovations in biosensors for COVID-19 mass testing

Electrical pulse-induced electrochemical biosensor for hepatitis E virus detection

Nanobiosensors in diagnostics. Nanobiomedicine (Rij)

Electrochemical biosensors for pathogen detection

And others. Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor

Potential antivirals and antiviral strategies against SARS coronavirus infections

Anti-SARS coronavirus agents: a patent review (2008 -present)

Peptidelike and small-molecule inhibitors against Covid-19

Broad-spectrum antiviral therapeutics

Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies

Development and evaluation of a CRISPR-based diagnostic for 2019-novel coronavirus

Perspectives for repurposing drugs for the coronavirus disease 2019

Chloroquine and hydroxychloroquine in the context of COVID-19

Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know

Chloroquine and Hydroxychloroquine in Covid-19

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Short-term dexamethasone in Sars-CoV-2 patients

Covid-19: demand for dexamethasone surges as RECOV-ERY trial publishes preprint

Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19)

COVID-19, chloroquine repurposing, and cardiac safety concern: chirality might help. Molecules

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial

Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor

Hydrophobic drug delivery by self-assembling triblock copolymer-derived nanospheres

Effect of tyrosine derived triblock copolymer compositions on nanosphere self-assembly and drug delivery

Functionalized nanospheres for targeted delivery of paclitaxel

Formulation strategy for the delivery of cyclosporine a: comparison of two polymeric nanospheres

Recent research and development of PLGA/PLA microspheres/nanoparticles: a review in scientific and industrial aspects

Tyrosine-derived nanospheres for enhanced topical skin penetration

drug-eluting stents: a new frontier for the treatment of coronary artery disease

Ultrafast and fast bioerodible electrospun fiber mats for topical delivery of a hydrophilic peptide

Electrospun nanofibrous polymeric scaffold with targeted drug release profiles for potential application as wound dressing

Inhalable nanoparticulate powders for respiratory delivery

Inhalation of nanoparticlebased drug for lung cancer treatment: advantages and challenges

Inhaled nano-and microparticles for drug delivery

Local delivery of mometasone furoate from an eluting endotracheal tube

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?

Cost of extracorporeal membrane oxygenation: evidence from the Rikshospitalet university hospital

Applied uses of extracorporeal membrane oxygenation therapy

Microparticle, nanoparticle, and stem cellbased oxygen carriers as advanced blood substitutes

Polymer-based nanomaterials and applications for vaccines and drugs

Extracorporeal stromal cell therapy for subjects with dialysis-dependent acute kidney injury

Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure

Long-term superior performance of a stem cell/hepatocyte device for the treatment of acute liver failure

Clearance of chloroquine and hydroxychloroquine by the seraph® 100 microbind® affinity blood filterapproved for the treatment of COVID-19 patients

In vitro elimination of anti-infective drugs by the seraph® 100 microbind® affinity blood filter

Removal of Carbapenem-resistant Enterobacteriaceae (CRE) from blood by heparin-functional hemoperfusion media

984: removal of cytomegalovirus from blood by heparin-functional hemoperfusion media

Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases

The SARS-CoV-2 vaccine pipeline: an overview

Integrating biomaterials and immunology to improve vaccines against infectious diseases

Biomaterial strategies for immunomodulation

Skin immunization with influenza vaccines

Lack of pain associated with microfabricated microneedles

Development of a thermostable microneedle patch for polio vaccination

Co-Delivery of M2e Virus-Like Particles with Influenza Split Vaccine to the Skin Using Microneedles Enhances the Efficacy of Cross Protection

Feasibility of Hepatitis B Vaccination by Microneedle Patch: Cellular and Humoral Immunity Studies in Rhesus Macaques

Microneedle array delivered recombinant coronavirus vaccines: immunogenicity and rapid translational development

Differential functional effects of biomaterials on dendritic cell maturation

Singlestep immunization using a controlled release, biodegradable polymer with sustained adjuvant activity

Airborne transmission of SARS-CoV-2: the world should face the reality

Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1

Antiviral and antibacterial nanostructured surfaces with excellent mechanical properties for hospital applications

Preparation, application and testing of permanent antibacterial and antiviral coatings

A review of the biomaterials technologies for infection-resistant surfaces

A smart multi-functional coating based on anti-pathogen micelles tethered with copper nanoparticles via a biosynthesis method using l-vitamin C

Surface Coating to Prevent the Spread of COVID-19

Antiviral and antibacterial polyurethanes of various modalities

Different virucidal activities of hyperbranched quaternary ammonium coatings on poliovirus and influenza virus

Bactericidal and virucidal ultrathin films assembled layer by layer from polycationic N-alkylated polyethylenimines and polyanions

22 -smart materials for personal protective equipment: tendencies and recent developments

Metallic copper as an antimicrobial surface

Putting copper into action: copper-impregnated products with potent biocidal activities

Comparison of the antiviral effect of solid-state copper and silver compounds

Colloidal silver

Coronavirus update: FDA and FTC warn seven companies selling fraudulent products that claim to treat or prevent COVID-19

Mode of antiviral action of silver nanoparticles against HIV-1

Silver nanoparticles as potential antiviral agents

Toxicity of silver nanoparticles in biological systems: does the complexity of biological systems matter?

Antiviral activity of gold/copper sulfide core/shell nanoparticles against human norovirus virus-like particles

Antiviral activity of silver nanoparticle:chitosan composites against H1N1 influenza a virus

The molecular mechanisms of copper and silver ion disinfection of bacteria and viruses

Song D and others. Porous gold nanoparticles for attenuating infectivity of influenza a virus

Virucidal activity of gold nanoparticles synthesized by green chemistry using garlic extract

Antiviral activities of Cu2+ ions in viral prevention, replication, RNA degradation, and for antiviral efficacies of lytic virus, ROS-mediated virus, copper chelation

Toxicity of nanoparticles and an overview of current experimental models

Exploring vivo toxicity assessment of copper oxide nanoparticle in Wistar rats

Cytotoxicity study of textile fabrics impregnated with CuO nanoparticles in mammalian cells

Effectiveness of nanomaterial copper cold spray surfaces on inactivation of influenza a virus

Inactivation of high and low pathogenic avian influenza virus H5 subtypes by copper ions incorporated in zeolite-textile materials

Developing novel antimicrobial and antiviral textile products

The Trustees of Columbia University in the City of New York, assignee. Antiviral glove. US patent US005133090A

Chapter 15 -surfactants

From renewable vegetables resources to microorganisms: new trends in surfactants

Sanitizing agents for virus inactivation and disinfection

Dynamic surface properties of nonionic surfactant solutions

Characterization and control of surfactantmediated norovirus interactions

Benzalkonium chlorides: uses, regulatory status, and microbial resistance

Comparative study of mechanisms of herpes simplex virus inactivation by sodium lauryl sulfate and nlauroylsarcosine

Cetylpyridinium chloride (CPC) exhibits potent, rapid activity against influenza viruses in vitro and in vivo

Toxicity of anionic detergents determined by Saccharomyces cerevisiae microarray analysis

Efficacy of five commercial disinfectants and one anionic surfactant against equine herpesvirus type 1

The influence of the size of the hydrophilic group on the miscibility of zwitterionic and nonionic surfactants in mixed monolayers and micelles

Mechanism of inactivation of influenza viruses by immobilized hydrophobic polycations

Biosurfactants: potential applications in medicine

Comparison of synthetic surfactants and biosurfactants in enhancing biodegradation of polycyclic aromatic hydrocarbons

Biosurfactant: production and application

Microbial biosurfactants production, applications and future potential

Mechanism of inactivation of enveloped viruses by the biosurfactant surfactin from Bacillus subtilis

Potential therapeutic applications of microbial surface-active compounds

Edible coating of fruits vegetables: a review

Polymers and biopolymers with antiviral activity: potential applications for improving food safety

Recent advances on polysaccharides, lipids and protein based edible films and coatings: a review

Incorporation Of Selected Plant Extracts into Edible Chitosan Films and the Effect on the Antiviral

Efficacy of cinnamaldehyde against enteric viruses and its activity after incorporation into biodegradable multilayer systems of interest in food packaging

Suppression of norovirus by natural phytochemicals from Aloe vera and Eriobotryae folium

Antiviral activity of alginate-oleic acid based coatings incorporating green tea extract on strawberries and raspberries

A review of the antiviral role of green tea catechins

Modified cyclodextrins as broad-spectrum antivirals

Respiratory virus shedding in exhaled breath and efficacy of face masks

Do N95 respirators provide 95% protection level against airborne viruses, and how adequate are surgical masks?

USFDA 2020. N95 respirators and surgical masks (face masks)

Standard specification for performance of materials used in medical face masks

A new material for airborne virus filtration

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The need for fully bio-based facemasks to counter coronavirus outbreaks: a perspective

The environmental dangers of employing single-use face masks as part of a COVID-19 exit strategy

A novel anti-influenza copper oxide containing respiratory face mask

Virus-removing filter

Mitsui Norin Co., Ltd., assignee. Antiviral filter air cleaner impregnated with tea extract. US patent US5747053

Mitsui Norin Co., Ltd., assignee. Gargling cup, antiviral mask, antiviral filter, antifungal, antibacterial, and antiviral filter air cleaner and air-cleaner humidifier. US patent US5888527

Preclinical in vitro activity of QR-435 against influenza a virus as a virucide and in paper masks for prevention of viral transmission

Aerosol filtration efficiency of common fabrics ised in respiratory cloth masks

Can breathing circuit filters help prevent the spread of influenza A (H1N1) virus from intubated patients?

Secondhand aerosol exposure during mechanical ventilation with and without expiratory filters: an invitro study

Methods for air cleaning and protection of building occupants from airborne pathogens

Application of corona discharge-generated air ions for filtration of aerosolized virus and inactivation of filtered virus

Inactivation of airborne viruses using vacuum ultraviolet photocatalysis for a flow-through indoor air purifier with short irradiation time

Adsorption of viruses to charge-modified silica

Unipolar charging of fine and ultrafine particles using carbon fiber ionizers

Ionizing air affects influenza virus infectivity and prevents airborne-transmission

Membranes in water and wastewater disinfection -review

Cationically modified membranes using covalent layer-by-layer assembly for antiviral applications in drinking water

How to cite this article

Opportunities for biomaterials to address the challenges of COVID-19